medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 3

<< Back Next >>

Med Int Mex 2018; 34 (3)

Rheumatoid vasculitis as first manifestation of rheumatoid arthritis

Marín-Hernández D, Orrantia-Vértiz M, Barragán-Garfias JA, Duarte-Mote J

Language: Spanish
References: 24
Page: 480-485
PDF size: 369.95 Kb.


ABSTRACT

The rheumatoid vasculitis is the most serious complication of rheumatoid arthritis, with high morbidity and mortality. It is an inflammatory process that affects small and medium vessels and that has heterogeneous manifestations, being the cutaneous lesions and neuropathy the most common. Its incidence has declined in the last decades because of the early use of disease modifying antirheumatic drugs. Despite the use of cyclophosphamide and the existence of biologic drugs, achieving the control of the disease continues to be a challenge. We present the case of a 50 year-old man, without relevant antecedents, only tabaco use, that presented with a vasculitic neuropathy, rheumatoid factor and cyclic citrullinated peptide antibody positive. This bibliographic review has the intention to update the knowledge of this entity and to be considered a differential diagnosis.


REFERENCES

  1. Bartels AJ. Rheumatoid vasculitis: Vanishing menace or target for new treatments? Curr Rheumatol Rep 2010;12(6):414-419.

  2. Lanzillo BPN. Subclinical peripheral nerve involvement in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1196-1202.

  3. Turesson C. Association of HLA–C3 and Smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(9):2776-2783.

  4. Laskaria K. Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis? Ann Rheum Dis 2010;69:469-471.

  5. Voskuyl AE. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 2003;62:407-413.

  6. Makol A, Matteson EL, et al. Rheumatoid vasculitis: an update. Curr Opin Rheumatol 2015 Jan; 27(1):63-70.

  7. Ntatsaki E. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology 2014;53:145-152.

  8. Genta MS. Systemic rheumatoid vasculitis: a review. Semin Arthr Rheum 2006;36:88-98.

  9. Hellmann MJN. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:929-930.

  10. Gorman JD. Particular HLA–DRB1 Shared Epitope Genotypes Are Strongly Associated With Rheumatoid Vasculitis. Arthritis Rheum 2004;50 (11):3476-3484.

  11. Kaye O. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996;23:253-257.

  12. Chen KR. Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002;147:905-913.

  13. Cojocaru M. New insight into the rheumatoid vasculitis. Romanian J Inl Med 2015;53(2):128-132.

  14. Maher LV. Successful treatment of rheumatoid vasculitisassociated foot drop with rituximab. Rheumatology (Oxford) 2006;45:1450-1451.

  15. Genta M. Systemic rheumatoid vasculitis: A review. Semin Arthr Rheum 2006;36:88-98.

  16. Chadha P. Burning vasculitis. Br Med J Case Reports 2016;1-4.

  17. Puechal X. Antitumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008;67:880-884.

  18. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984;76(3):377-384.

  19. Scott DG. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981;60:288-297.

  20. Scott DGI. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis andvasculitis: comparative and serial studies during cytotoxic therapy. J Clin Exp Immunol 1981;43:54-56.

  21. Voskuyl AE. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996;55:190-192.

  22. Watts RA. Rheumatoid vasculitis: becoming extinct? Rheumatology 2004;43:920-923.

  23. Puéchal X. Associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res 2012;64(3):331-339.

  24. Puéchal X. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. Arthritis Rheum 1995;38 (11):1618-1629.




2020     |     www.medigraphic.com